MYND Life Sciences Inc.
MYND
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 30.38% | 58.05% | 55.62% | 183.15% | 39.38% |
| Total Depreciation and Amortization | -85.71% | -91.38% | -94.05% | -91.95% | -92.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -83.11% | -65.76% | -- | -294.80% | 75.92% |
| Change in Net Operating Assets | 26.26% | -44.33% | -51.77% | -53.93% | -64.61% |
| Cash from Operations | 97.64% | 236.78% | -375.73% | -467.15% | -3,275.00% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 113.51% | -- | 100.00% | 100.00% |
| Cash from Investing | -- | 100.00% | -- | 757.20% | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -318.18% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -66.67% | 2,161.54% | -3,450.00% | -90.00% | 94.23% |